PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
PIK3CA
breast cancer
circulating tumor DNA
circulating tumor cells
liquid biopsy
mutation analysis
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
27
08
2018
revised:
24
06
2019
accepted:
28
06
2019
pubmed:
30
6
2019
medline:
19
6
2020
entrez:
30
6
2019
Statut:
ppublish
Résumé
Liquid biopsy analysis, mainly based on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), provides an extremely powerful tool for the molecular profiling of cancer patients in real time. In this study, we directly compared PIK3CA hotspot mutations (E545K, H1047R) in EpCAM-positive CTCs and paired plasma-ctDNA in breast cancer (BrCa). PIK3CA hotspot mutations in CTCs and ctDNA were analyzed using our previously developed highly sensitive (0.05%), specific, and validated assay in plasma-ctDNA from 77 early and 73 metastatic BrCa patients and 40 healthy donors. We further analyzed and directly compared PIK3CA hotspot mutations in DNAs isolated from CellSearch
Identifiants
pubmed: 31254443
doi: 10.1002/1878-0261.12540
pmc: PMC6887588
doi:
Substances chimiques
Circulating Tumor DNA
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2515-2530Informations de copyright
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Clin Cancer Res. 2017 Jan 1;23(1):88-96
pubmed: 27334837
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Clin Chem. 2013 Jan;59(1):270-9
pubmed: 23136251
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
J Natl Cancer Inst. 2018 Jun 1;110(6):560-567
pubmed: 29659933
Cancer Res. 2004 Nov 1;64(21):7678-81
pubmed: 15520168
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
J Clin Oncol. 2016 Feb 10;34(5):419-26
pubmed: 26503204
Mol Oncol. 2013 Oct;7(5):976-86
pubmed: 23895914
BMC Cancer. 2016 Jul 25;16:522
pubmed: 27456970
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Oncotarget. 2017 May 26;8(44):77928-77941
pubmed: 29100436
Lancet Oncol. 2012 Jul;13(7):688-95
pubmed: 22677156
Curr Biol. 2003 Aug 5;13(15):1259-68
pubmed: 12906785
J Clin Oncol. 2002 Aug 15;20(16):3404-12
pubmed: 12177100
J Natl Cancer Inst. 2014 May 15;106(5):null
pubmed: 24832787
Mol Cancer Ther. 2011 Mar;10(3):558-65
pubmed: 21216929
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
Oncotarget. 2016 Dec 20;7(51):85349-85364
pubmed: 27863403
Clin Chem. 2011 Aug;57(8):1169-77
pubmed: 21700955
BMC Res Notes. 2009 Apr 29;2:66
pubmed: 19402901
Br J Cancer. 2017 Mar 14;116(6):726-730
pubmed: 28183140
Ann Oncol. 2015 Mar;26(3):510-6
pubmed: 25471333
Mol Oncol. 2015 Apr;9(4):749-57
pubmed: 25539732
J Mol Diagn. 2018 May;20(3):316-325
pubmed: 29474983
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Mol Oncol. 2016 Oct;10(8):1330-43
pubmed: 27491860
Nat Rev Clin Oncol. 2018 May;15(5):273-291
pubmed: 29508857
J Mol Diagn. 2015 May;17(3):209-24
pubmed: 25908243
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Clin Cancer Res. 2014 Nov 15;20(22):5823-34
pubmed: 25398847
Clin Cancer Res. 2018 Mar 15;24(6):1500-1510
pubmed: 29284708
Front Med. 2017 Dec;11(4):522-527
pubmed: 28744793
BMC Cancer. 2011 Oct 04;11:422
pubmed: 21967632
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
Clin Chem. 2018 Feb;64(2):297-306
pubmed: 29122836
Int J Mol Sci. 2017 Aug 31;18(9):null
pubmed: 28858218
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Adv Exp Med Biol. 2015;867:341-67
pubmed: 26530376
Nat Commun. 2018 Mar 1;9(1):896
pubmed: 29497091
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Clin Cancer Res. 2015 Nov 1;21(21):4786-800
pubmed: 26527805
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Clin Cancer Res. 2007 Oct 15;13(20):6064-9
pubmed: 17947469
Oncotarget. 2017 Jun 14;8(32):52142-52155
pubmed: 28881720
Breast Cancer Res Treat. 2017 Jun;163(2):219-230
pubmed: 28271309
Clin Chem. 2011 Mar;57(3):421-30
pubmed: 21245367
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745